International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials (Q56447686)

From Wikidata

Jump to navigation Jump to search

article

Language	Label	Description	Also known as
English	International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: Correlates of high Ad5 titers and implications for potential HIV vaccine trials	article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

International epidemiology of human pre-existing adenovirus (Ad) type-5, type-6, type-26 and type-36 neutralizing antibodies: correlates of high Ad5 titers and implications for potential HIV vaccine trials (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Esper Georges Kallas

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

14

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

11

object named as

Nathan D Wolfe

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

author name string

Lisa Kierstead

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Vladimir Novitsky

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Bernard Mbewe

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Punee Pitisuttithum

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Mauro Schechter

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Miguel Aste-Amezaga

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

T Christopher Mast

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Swati B Gupta

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Alexander A Nikas

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Danilo R Casimiro

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Walter L Straus

15

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

John W Shiver

16

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

language of work or name

0 references

publication date

17 November 2009

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

28

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

950-957

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Adenoviruses as vaccine vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Adenovirus vector-based vaccines for human immunodeficiency virus type 1.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Immune responses to adenovirus and adeno-associated virus in humans.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Plasmid chemokines and colony-stimulating factors enhance the immunogenicity of DNA priming-viral vector boosting human immunodeficiency virus type 1 vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Overcoming immunity to a viral vaccine by DNA priming before vector boosting

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Comparative Immunogenicity in Rhesus Monkeys of DNA Plasmid, Recombinant Vaccinia Virus, and Replication-Defective Adenovirus Vectors Expressing a Human Immunodeficiency Virus Type 1 gag Gene

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Immunogenicity of recombinant fiber-chimeric adenovirus serotype 35 vector-based vaccines in mice and rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

HIV seroconversion without infection after receipt of adenovirus-vectored HIV type 1 vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Neutralizing antibodies against 33 human adenoviruses in normal children in Rome

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

A novel adenovirus type 6 (Ad6)-based hepatitis C virus vector that overcomes preexisting anti-ad5 immunity and induces potent and broad cellular immune responses in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Replication-deficient human adenovirus type 35 vectors for gene transfer and vaccination: efficient human cell infection and bypass of preexisting adenovirus immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Neutralizing antibodies to adenovirus serotype 5 vaccine vectors are directed primarily against the adenovirus hexon protein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Prevalence of neutralizing antibodies to adenoviral serotypes 5 and 35 in the adult populations of The Gambia, South Africa, and the United States

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Large epidemic of adenovirus type 4 infection among military trainees: epidemiological, clinical, and laboratory studies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Immune control of an SIV challenge by a T-cell-based vaccine in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Age-related decrease in adenovirus-specific T cell responses.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Enrolling adolescents in HIV vaccine trials: reflections on legal complexities from South Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Age dependence of adenovirus-specific neutralizing antibody titers in individuals from sub-Saharan Africa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Novel replication-incompetent adenoviral B-group vectors: high vector stability and yield in PER.C6 cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Safety of local delivery of low- and intermediate-dose adenovirus gene transfer vectors to individuals with a spectrum of morbid conditions

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Safety and Immunogenicity of a Replication‐Incompetent Adenovirus Type 5 HIV‐1 Clade Bgag/pol/nefVaccine in Healthy Adults

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Replication-defective adenovirus vectors with multiple deletions do not induce measurable vector-specific T cells in human trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Immunogenicity of recombinant adenovirus serotype 35 vaccine in the presence of pre-existing anti-Ad5 immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Viral vectors in malaria vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2009.10.145

7 January 2021

Identifiers

10.1016/J.VACCINE.2009.10.145

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19925902%20AND%20SRC:MED&resulttype=core&format=json

12 February 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q56447686&oldid=2081764237"